PRTA Prothena Corp Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTA

Price (delayed)

$8.68

Market cap

$445.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$164.4M

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 42

Prothena Corporation plc is a clinical-stage biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and ...

Highlights
The quick ratio has surged by 144% since the previous quarter
The net income has soared by 85% YoY and by 71% from the previous quarter
The company's equity fell by 12% YoY and by 8% QoQ
The company's gross profit fell by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.prothena.com
Peers: ALKS ALNY AMRN

Key stats

What are the main financial stats of PRTA

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-3.45%
1 week
5.34%
1 month
-8.15%
1 year
4.45%
YTD
-9.11%
QTD
-11.34%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$54.53M
Gross profit
$54.53M
Operating income
-$55.51M
Net income
-$43.99M
Gross margin
100%
Net margin
-80.7%
Prothena's net margin has soared by 97% YoY and by 69% from the previous quarter
The operating margin has soared by 96% year-on-year and by 50% since the previous quarter
The net income has soared by 85% YoY and by 71% from the previous quarter
Prothena's operating income has surged by 80% YoY and by 53% QoQ

Price vs fundamentals

How does PRTA's price correlate with its fundamentals

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
1.58
P/S
8.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.01
The company's EPS has surged by 85% YoY and by 70% QoQ
PRTA's price to book (P/B) is 50% lower than its 5-year quarterly average of 3.3 and 9% lower than its last 4 quarters average of 1.8
The company's equity fell by 12% YoY and by 8% QoQ
PRTA's price to sales (P/S) is 83% lower than its 5-year quarterly average of 49.2 and 70% lower than its last 4 quarters average of 29.0
Prothena's revenue has decreased by 6% from the previous quarter

Efficiency

How efficient is Prothena business performance
The company's return on sales has surged by 97% YoY and by 56% QoQ
Prothena's return on assets has surged by 78% YoY and by 69% QoQ
The ROE has soared by 78% YoY and by 70% from the previous quarter

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The quick ratio has surged by 144% since the previous quarter
PRTA's current ratio has surged by 140% since the previous quarter
Prothena's debt is 98% less than its equity
Prothena's debt to equity has decreased by 33% YoY
Prothena's debt has decreased by 29% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.